Showing 4671-4680 of 6036 results for "".
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480805/Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, th
- Apellis Announces Results from New Survey Revealing the Emotional Burden Caused by Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-results-from-new-survey-revealing-the-emotional-burden-caused-by-geographic-atrophy-ga/2480801/Apellis Pharmaceuticals announced results from a global survey conducted by The Harris Poll, which found that living with geographic atrophy (GA) can cause a substantial emotional burden and impact on independence. GA is a leading cause of blindness that affects more than 5 million people wo
- Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational NOV03 at ASCRShttps://modernod.com/news/bausch-lomb-presents-data-from-first-pivotal-phase-3-trial-of-investigational-nov03-at-ascrs/2480800/Bausch + Lomb and Novaliq announced that data from the first pivotal phase 3 trial (GOBI) of NOV03 (perfluorohexyloctane), which is being investigated as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibom
- Ocular Therapeutix to Present Preclinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-the-2022-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2480797/Ocular Therapeutix announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually. “At this year’s annual meeting, we are thrilled to be presenting c
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Haag-Streit Launches the Eyestar 900 Anterior Chamber Suitehttps://modernod.com/news/haag-streit-launches-the-eyestar-900-anterior-chamber-suite/2480794/Haag-Streit has announced the launch of the Eyestar 900 Anterior Chamber Suite (AC-Suite) to compliment the Cataract Suite. The AC-Suite is designed to meet the growing demand for improved outcomes in cataract and refractive surgery. The Eyestar 900 is based on swep
- Ziemer Receives FDA Clearance for the FEMTO Z8 NEOhttps://modernod.com/news/ziemer-receives-fda-clearance-for-the-femto-z8-neo/2480792/Ziemer Ophthalmic Systems has received FDA clearance for its latest femtosecond laser, the FEMTO Z8 NEO—the successor of Femtosecond Laser LDV Z8. The FEMTO Z8 NEO provides advanced hardware, as well as new and improved software applications. The newly designed platform offer
- Ocuphire Appoints Jay Pepose, MD, PhD, as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyeceleratorhttps://modernod.com/news/ocuphire-appoints-jay-pepose-md-phd-as-chief-medical-advisor-and-announces-upcoming-presentations-at-ascrs-2022-and-eyecelerator/2480777/Ocuphire Pharma announced the appointment of Jay Pepose, MD, PhD, as its Chief Medical Advisor. In addition, Dr. Pepose, Dr. Ralph Chu, and Dr. Marguerite McDonald will deliver three presentations on Nyxol at the American Society of Cataract and Refractive Surgery (ASCRS) which will
- Lumibird Medical Launches Nd:YAG Laser Capsulohttps://modernod.com/news/lumibird-medical-launches-new-ndyag-laser-capsulo/2480767/Lumibird Group, the parent company of Quantel Medical, announced the launch of the Capsulo Nd:YAG laser. Lumibird says the device is designed to be a fully integrated, versatile laser platform, enabling efficient and accurate capsulotomy and iridotomy treatments. &ld